 Astellas Pharma Plc OTCMKTS: ALPMY has reported positive topline results from two Phase 3 trials, SKYLIGHT 1 and SKYLIGHT 2, evaluating an oral non-hormonal compound, fezolinetant, for treating moderate to severe vasomotor symptoms VMS, specifically hot flashes associated with menopause. Results showed that both trials met all four co-primary endpoints. 